InvestorService: Genmab, to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference

February 05, 2007 02:13 ET | Source: Genmab A/S Genmab A/S

Genmab's CEO will present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City on February 7.

Attachments

102611.pdf...

Recommended Reading

December 07, 2025 07:50 ET | Source: Genmab A/S

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R2) resulted in statistically significant and...
Read More

$Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma$
December 06, 2025 09:30 ET | Source: Genmab A/S

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Media ReleaseCOPENHAGEN, Denmark; December 6, 2025 New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in...
Read More